IDEXX Laboratories, Inc. $IDXX Holdings Lifted by Teacher Retirement System of Texas

Key Points

• Teacher Retirement System of Texas increased its stake in IDEXX by 85.3% in Q4, now owning 65,734 shares worth about $44.47 million (≈0.08% of the company).
• Company insiders sold a total of 45,957 shares last quarter valued at about $29.86 million, reducing insider ownership to 0.79%.
• Analyst sentiment is mixed but averages a "Moderate Buy" with a $760 price target; IDEXX beat Q4 EPS ($3.08 vs. $2.93) and provided FY2026 EPS guidance of 14.29–14.80 (analyst average 14.54).

Teacher Retirement System of Texas increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 85.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,734 shares of the company's stock after buying an additional 30,268 shares during the quarter. Teacher Retirement System of Texas owned 0.08% of IDEXX Laboratories worth $44,471,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. HB Wealth Management LLC boosted its position in IDEXX Laboratories by 4.8% during the fourth quarter. HB Wealth Management LLC now owns 4,139 shares of the company's stock valued at $2,800,000 after purchasing an additional 189 shares during the last quarter. Caprock Group LLC grew its stake in shares of IDEXX Laboratories by 4.1% in the 4th quarter. Caprock Group LLC now owns 8,041 shares of the company's stock valued at $5,440,000 after buying an additional 320 shares in the last quarter. M&T Bank Corp grew its stake in shares of IDEXX Laboratories by 1,923.9% in the 4th quarter. M&T Bank Corp now owns 71,180 shares of the company's stock valued at $48,155,000 after buying an additional 67,663 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of IDEXX Laboratories by 0.8% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 114,154 shares of the company's stock valued at $77,426,000 after buying an additional 909 shares in the last quarter. Finally, Optas LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $398,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on IDXX. Wall Street Zen cut IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 28th. Citigroup began coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a "neutral" rating and a $650.00 price target for the company. UBS Group lowered their price target on IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating for the company in a research note on Tuesday, February 3rd. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating for the company in a research note on Tuesday, March 31st. Finally, Barclays cut their target price on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a report on Thursday, February 5th. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average price target of $760.00.

Insider Buying and Selling

In other news, EVP Michael G. Erickson sold 5,371 shares of the firm's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares of the company's stock, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of the firm's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the sale, the director directly owned 648 shares in the company, valued at approximately $407,345.76. This represents a 69.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 in the last quarter. Insiders own 0.79% of the company's stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $560.93 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $424.48 and a fifty-two week high of $769.98. The stock's 50-day moving average is $596.08 and its two-hundred day moving average is $653.24. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The firm has a market cap of $44.55 billion, a P/E ratio of 42.92, a price-to-earnings-growth ratio of 3.51 and a beta of 1.72.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the company earned $2.53 earnings per share. The business's revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 14.54 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.